Scarica l'app Stockscreener
31.39
2.82%
0.86
Dopo l'orario di chiusura:
31.39
Precedente Chiudi:
$30.53
Aprire:
$30.89
Volume 24 ore:
854.32K
Relative Volume:
0.93
Capitalizzazione di mercato:
$2.76B
Reddito:
$218.71M
Utile/perdita netta:
$-113.70M
Rapporto P/E:
-24.08
EPS:
-1.3034
Flusso di cassa netto:
$-73.47M
1 W Prestazione:
-5.76%
1M Prestazione:
-0.88%
6M Prestazione:
+22.19%
1 anno Prestazione:
+74.29%
Intervallo 1D:
$30.84
$31.76
Intervallo di 1 settimana:
$29.57
$33.51
Portata 52W:
$13.45
$39.28
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Nome
Ideaya Biosciences Inc
Settore
Industria
Telefono
650-443-6209
Indirizzo
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
31.39 | 2.68B | 218.71M | -113.70M | -73.47M | -1.3034 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-09-18 | Iniziato | Guggenheim | Buy |
| 2025-09-04 | Iniziato | Barclays | Overweight |
| 2025-09-04 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Iniziato | TD Cowen | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-26 | Iniziato | Wells Fargo | Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-11-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2024-03-08 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Outperform |
| 2023-05-24 | Iniziato | Goldman | Buy |
| 2023-04-24 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-23 | Iniziato | Berenberg | Buy |
| 2023-02-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-28 | Iniziato | CapitalOne | Overweight |
| 2022-10-27 | Iniziato | Citigroup | Buy |
| 2022-08-15 | Downgrade | Stifel | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-10 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-11 | Iniziato | Guggenheim | Buy |
| 2020-10-07 | Iniziato | Wedbush | Outperform |
| 2020-09-01 | Iniziato | Northland Capital | Outperform |
| 2020-07-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-06 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-13 | Iniziato | ROTH Capital | Buy |
| 2019-10-17 | Iniziato | Oppenheimer | Outperform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-17 | Iniziato | Citigroup | Buy |
| 2019-06-17 | Iniziato | JP Morgan | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
Mostra tutto
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
RBC Capital reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada
Jefferies reiterates Ideaya Biosciences stock rating on trial delay By Investing.com - Investing.com Canada
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 6.1%Here's Why - MarketBeat
IDEAYA Biosciences Sees Unusually High Options Volume (NASDAQ:IDYA) - MarketBeat
Ideaya Biosciences stock maintained at Outperform by Mizuho on trial timing - Investing.com Canada
Citizens reiterates Ideaya Biosciences stock rating on mUM trial data By Investing.com - Investing.com Canada
IDEAYA delays darovasertib trial results to mid-April By Investing.com - Investing.com Canada
Cancer trial readout nears as IDEAYA targets first-half April lock - Stock Titan
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
IDYA Stock Price, Quote & Chart | IDEAYA BIOSCIENCES INC (NASDAQ:IDYA) - ChartMill
(IDYA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Barclays Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
IDEAYA Biosciences (IDYA) Gets a Buy from Mizuho Securities - The Globe and Mail
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs - Barchart.com
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
IDEAYA Biosciences, Inc. $IDYA Shares Purchased by Cinctive Capital Management LP - MarketBeat
Iron Triangle Partners LP Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
A Look At IDEAYA Biosciences (IDYA) Valuation After IDE892 Trial Enrollment And Pipeline Refocus - simplywall.st
IDEAYA Biosciences, Inc. $IDYA Position Increased by Baker BROS. Advisors LP - MarketBeat
IDEAYA Biosciences Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
42,283 Shares in IDEAYA Biosciences, Inc. $IDYA Bought by WINTON GROUP Ltd - MarketBeat
Truist reiterates Ideaya Biosciences stock rating on MTAP program By Investing.com - Investing.com Canada
IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating - TipRanks
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update - Finviz
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial - GuruFocus
Ideaya Biosciences announces first-patient-in for phase 1 trial of IDE892 - marketscreener.com
Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE892 - TradingView
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update – Company Announcement - Financial Times
IDEAYA Biosciences announces the latest development timeline for its Cdkn2a project - Bitget
IDYA SEC FilingsIdeaya Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
(IDYA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Goldman Sachs Maintains IDEAYA Biosciences (IDYA) Neutral Recommendation - MSN
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC - finance.yahoo.com
Aug Mood: What is IDEAYA Biosciences Incs P E ratio telling usJuly 2025 Action & Fast Gain Stock Tips - baoquankhu1.vn
Fisher Asset Management LLC Lowers Stock Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDYA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up on Insider Buying Activity - MarketBeat
IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: A Biotech Gem With 51% Upside Potential - DirectorsTalk Interviews
Did IDEAYA’s (IDYA) First-in-Human IDE034 Trial Just Redefine Its Targeted Oncology Strategy? - simplywall.st
Ideaya Biosciences Insider Bought Shares Worth $1,647,890, According to a Recent SEC Filing - marketscreener.com
Insider Buying: IDEAYA Biosciences (NASDAQ:IDYA) Director Buys 50,000 Shares of Stock - MarketBeat
Ideaya Biosciences (IDYA) director Stein buys $1.65 million in stock By Investing.com - Investing.com Australia
Ideaya Biosciences (IDYA) director Stein buys $1.65 million in stock - Investing.com
Director Jeffrey Stein buys 50,000 IDEAYA Biosciences (IDYA) shares in market - Stock Titan
IDEAYA Biosciences Director Jeffrey Stein Acquires 50,000 Shares - TradingView
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - The AI Journal
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 - Via TT
Assessing IDEAYA Biosciences (IDYA) Valuation After IDE034 First-In-Human Dosing Milestone - Yahoo Finance
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA's First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 - lelezard.com
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034 – News Hub - Medianet News Hub
Ideaya Biosciences Inc Azioni (IDYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):